3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
17
Carcinoma, Ovarian Epithelial
12
Breast Neoplasms
8
Fallopian Tube Neoplasms
7
Lung Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Colorectal Neoplasms
4
Small Cell Lung Carcinoma
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Testicular Neoplasms
2
Testicular Germ Cell Tumor
2
Squamous Cell Carcinoma of Head and Neck
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Colonic Neoplasms
2
Interventions
pembrolizumab
24
Nivolumab
15
Magnetic Resonance Spectroscopy
7
Ipilimumab
6
avelumab
5
atezolizumab
5
Specimen Handling
5
Docetaxel
4
lenvatinib
3
durvalumab
3
Paclitaxel
3
Cyclophosphamide
3
Carboplatin
3
fludarabine
2
cabozantinib
2
aldesleukin
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
FAPI-46
2
zanidatamab
1
veliparib
1
tislelizumab
1
spartalizumab
1
soluble LAG-3 protein, human
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
sargramostim
×
Gynecologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled